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Abstract Soluble fibroblast growth factor receptors (FGFRs)
have been identified in multiple biological fluids, including blood.
Efforts to examine the biological properties of these proteins
have been hampered by the incomplete chemical characterization
of the receptors within the second half of the third immunoglo-
bulin (Ig)-like domain, where alternative splicing leads to
receptor variants with different ligand binding properties. Using
mass spectrometry techniques, we have mapped the soluble
FGFRs to the secreted receptor, FGFR1(IIIa), the two and three
Ig-like domain isoforms of FGFR1(IIIc) and a carboxyl-terminal
cleavage peptide from the two and three Ig-like domain isoforms
of FGFR1(IIIb). The secreted FGFR is produced by the
translation of an alternatively spliced transcript and the cleaved
receptors are released by ectodomain shedding of the transmem-
brane receptors. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Soluble receptors are part of an expanding class of regula-
tory molecules that are derived from the extracellular domains
of integral plasma membrane proteins (for review see [1,2]).
Their ligand binding a⁄nities are often similar to those of the
cell surface receptor, suggesting that their biological role is to
modulate the systemic and local action of their ligands by
competing with the cell surface receptors for ligand binding.
A few soluble receptors are generated by the secretion of
alternatively spliced mRNA transcripts, which have been
identi¢ed in cDNA libraries and/or predicted from genomic
sequences [1]. However, most soluble receptors are generated
by proteolytic cleavage at the cell surface by sheddases, many
of which are members of the ADAMs (a disintegrin and met-
alloprotease) family of metalloproteases [2]. The shedding of
soluble receptors provides a key mechanism for the downre-
gulation of cell surface receptors and the release of biologi-
cally active proteins into the circulation [2^6].
We have identi¢ed soluble ¢broblast growth factor recep-
tors (FGFRs) in multiple biological £uids, as well as in the
extracellular matrix of vascular endothelial cells [7^9]. One
group of soluble FGFRs has a molecular mass ranging
from 55 to 60 kDa and consists of the two immunoglobulin
(Ig)-like domain isoforms of FGFR1. A second group has a
molecular mass of 85 kDa and corresponds to the three Ig-like
domain isoforms of FGFR1. It has been proposed that the
soluble FGFRs function as endogenous inhibitors of the bio-
logical activities of the FGF family of proteins in vivo, both in
the circulation and in the extracellular matrix [7,10]. However,
until the proteins have been fully structurally characterized,
the question of their biological properties remains largely
speculative.
There is structural and functional diversity within the high
a⁄nity FGFR gene family [11]. There are four related FGFR
gene family members and among these, FGFR1, 2, and 3
encode di¡erent isoforms that are generated by alternative
splicing of mRNA transcripts [12^16]. These isoforms include
receptors lacking Ig-like domain I and/or containing alterna-
tive sequences in the second half of Ig-like domain III [13,14]
(Fig. 1). The latter group includes variants that consist of two
alternative transmembrane forms of the high a⁄nity FGFR
(IIIb or IIIc) and a secreted form that lacks the transmem-
brane domain (IIIa). This structural diversity has functional
relevance because the various isoforms of the transmembrane
FGFRs have di¡erent a⁄nities for the FGF family members
[17,18].
To understand the functional signi¢cance of the soluble
FGFRs, it is necessary to classify them according to the pres-
ence or absence of Ig-like domain I and the speci¢c exon (IIIa,
IIIb, or IIIc) encoding the second half of the Ig-like domain
III. To accomplish this goal, we performed matrix-assisted
laser desorption/ionization time-of-£ight (MALDI-TOF)
mass spectrometry (MS) and con¢rmed these results using
nanoelectrospray MS/MS or postsource decay (PSD) on tryp-
tic fragments of the soluble FGFRs puri¢ed from blood. Us-
ing sequence analysis programs, we mapped the second half of
the third Ig-like domain within the region coded by exons
IIIa, IIIb, and IIIc.
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2. Materials and methods
2.1. Materials
Human recombinant FGF-2 was expressed in Escherichia coli [19]
and puri¢ed using heparin-Sepharose a⁄nity chromatography and
ion-exchange chromatography as previously described [20]. Monoclo-
nal antibodies (Mab6) to the extracellular domain of the recombinant
FGFR1 [21] were raised in ascites £uid and puri¢ed over Protein G-
Sepharose columns (Amersham Pharmacia Biotech, Piscataway, NJ,
USA) [10].
2.2. Immunoblotting
Soluble FGFRs were identi¢ed by immunoblotting on 8% sodium
dodecyl sulfate^polyacrylamide agarose gel electrophoresis (SDS^
PAGE) gels. The proteins were transferred to nitrocellulose, blocked
for 1 h at room temperature with 5% non-fat milk in Tris-bu¡ered
saline (TBS), 0.1% Tween 20, and then immunoblotted overnight at
4‡C with 2 Wg/ml of Mab6 diluted in 5% bovine serum albumin in
TBS, 0.05% Tween 20. The blots were washed with TBS, 0.05%
Tween 20 and incubated for 1 h at room temperature with horseradish
peroxidase-conjugated goat anti-mouse antibodies (Bio-Rad) diluted
1/5000 in 5% non-fat milk in TBS, 0.1% Tween 20. The immunoblots
were developed with the Super Signal reagent (Pierce, Rockford, IL,
USA) according to the manufacturer’s instructions.
2.3. Puri¢cation of the soluble FGFRs from calf serum
The 85 kDa and the 55^60 kDa soluble FGFRs were puri¢ed from
1 l aliquots of newborn calf serum (Omega Scienti¢c, Tarzana, CA,
USA) using 8 ml HS a⁄nity columns (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) containing 10 mg recombinant FGF-2 accord-
ing to standard protocols [7]. The 2 M NaCl eluates from the FGF/
HS columns were concentrated using a Centriplus concentrator (Milli-
pore, Bedford, MA, USA) and loaded on a Model 491 Prep Cell
electrophoresis column (Bio-Rad, Hercules, CA, USA) containing
an 8% SDS^PAGE gel and eluted according to the manufacturer’s
protocol. The 55^60 kDa and the 85 kDa soluble FGFR fractions
were concentrated and deglycosylated using a combination of PNGase
F, sialidase A, Endo-O-glycosidase, L(1-4)galactosidase and glucos-
aminidase included in the GlycoPro deglycosylation kit (ProZyme,
San Leandro, CA, USA) according to the manufacturer’s instructions.
The deglycosylated proteins were separated on an 8% SDS^PAGE gel,
stained with GELCODE blue stain reagent, destained in water and
excised from the gel. For MS, the excised gel pieces were washed with
25 mM ammonium bicarbonate containing 30% acetonitrile, dried
and rehydrated in ammonium bicarbonate, pH 8.0. Modi¢ed sequence
grade trypsin (Promega, Madison, WI, USA) was added at a concen-
tration of 0.1 mg/ml and incubated at 30‡C overnight. The superna-
tant was removed and the tryptic fragments were extracted several
times using 60% acetonitrile/0.01% tri£uoroacetic acid (TFA) at 30‡C.
2.4. MALDI-TOF MS
All MS studies were performed by the Mass Spectrometry Core
Facility at The Scripps Research Institute. The masses of the digested
tryptic fragments were analyzed by MALDI-TOF-re£ectron using a
Voyager-Elite time-of-£ight mass spectrometer with delayed extrac-
tion (PerSeptive Biosystems, Inc., Framingham, MA, USA). A vol-
ume of 1 Wl of digested protein was placed directly on the MALDI
analysis plate, mixed with 1 Wl of matrix (K-cyano-4-hydroxy-cinnam-
ic acid) in a saturated solution of acetonitrile/water (50:50 v/v) with
0.25% (w/w) TFA and inserted into the MALDI ionization source for
analysis. The samples were irradiated with a nitrogen laser (Laser
Science, Inc.) operated at 337 nm. The laser beam was attenuated
onto the sample target by a neutral density ¢lter. Ions produced by
laser desorption were typically energetically stabilized during a de-
layed extraction period of 150 ns and were then accelerated through
the time-of-£ight mass analyzer with a 20 kV potential. Typically, the
spectra were an average of 128 laser pulses. The measurements were
internally calibrated and the peaks were assigned in the linear mode
with an accuracy of 1000 ppm. The monoisotopic mass was used to
assign peaks with masses 6 1400.0 Da and the average mass was used
to assign peaks with masses s 1400.0 Da. The exact mass measure-
ments were performed using the same MALDI instrument in the
re£ector mode with internal calibration of trypsin fragments
(VATVSLRP, MH 842.5099, monoisotopic mass) and (LGEH-
NIDVLEGNEQFINAAK, MH 2211.1046, monoisotopic mass).
PSD spectra were obtained for several peptides after isolation of a
precursor ion using timed-ion selection. The fragment ions were re-
£ected onto the ¢nal detector by scanning the re£ector voltage at the
following ratios: 1.0, 0.9, 0.81, 0.73, 0.66, 0.59, 0.53, 0.48, 0.43, and
0.39.
2.5. Mass mapping
The observed peptide masses were mapped to the expected tryptic
fragments of the FGFRs using the updated protein sequence analysis
program for MS, PAWS- (June 2000; PAWS- http://www.proteome-
trics.com/software/paws.htm). The human amino acid sequences used
for this analysis were derived from the GenBank accession numbers
described in Table 1. These include the secreted receptor
FGFR1(IIIa), and the extracellular domain of the two and the three
Ig-like loop isoforms of the transmembrane receptors, FGFR1(IIIb)
and FGFR1(IIIc).
2.6. Nanoelectrospray ionization (nanoESI)-MS/MS
The nanoESI-MS experiments are performed on an API III Perkin
Elmer SCIEX triple quadrupole mass spectrometer with a Protana
nanoESI source. The electrospray samples are typically introduced
into the mass analyzer at a rate of V40 nl/min. The positive and
negative ions, generated by charged droplet evaporation, enter the
analyzer through an interface plate and a 100 Wm ori¢ce, while the
declustering potential is maintained between 50 and 200 V to control
the collisional energy of the ions entering the mass analyzer. The
emitter voltage is typically maintained at 800 V. A curtain gas of
ultrapure nitrogen was pumped into the interface at a rate of
0.6 l/min to aid evaporation of solvent droplets and to prevent partic-
ulate matter from entering the analyzer. The digested protein (3 Wl)
was mixed with 7 Wl of MeOH and 0.5 Wl formic acid (for fragment
ion scan), 4 Wl of which was loaded into a palladium-coated boro-
silicate glass capillary and injected into the mass spectrometer. The
fragment ion scan was used to obtain the sequence information of the
interesting ions.
3. Results
3.1. Identi¢cation of the secreted FGFR, FGFR1(IIIa)
The MALDI-TOF mass spectrum of the 55^60 kDa soluble
FGFRs (Fig. 2) was mapped to the tryptic peptides of the
secreted FGFR, FGFR1(IIIa). The observed fragments
matched 53% of the total sequence of FGFR1(IIIa) and
57% of the unique sequence in the region encoded by exon
IIIa (Fig. 3). Exact mass measurements of two fragments,
Fig. 1. Structural features of the three and two Ig-like domain iso-
forms of the transmembrane FGFR1 receptor (which both exist as
IIIb or IIIc) and the two Ig-like domain isoform of the secreted
FGFR1(IIIa) [11,13]. The divergent amino acid sequences in iso-
forms IIIa, b and c are indicated by bold or wavy lines.
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MH 1300.6826 and MH 1217.6226, are within 0.9 and 2.7
ppm of the calculated exact masses of the tryptic peptides
(Table 2).
PSD-MALDI-TOF data support the identi¢cation of
FGFR1(IIIa). A PSD fragmentation pattern was obtained
on the tryptic peptide, MH = 1217.6226, which maps to
D[250^260]R in the region encoded by exon IIIa. The spec-
trum shown in Fig. 4 demonstrates the sequence-speci¢c frag-
mentation pattern of the common b and y ions, and the less
common a, b and x, z ions. The additional peaks in the spec-
trum consist of ions that were likely generated from other
peptides that were within the timed-ion selection window
used to isolate the peptide of interest. The inset shows the
major ion fragments that were found in the spectrum using
the nomenclature according to Biemann [22].
3.2. Identi¢cation of a cleaved two Ig-like domain isoform of
FGFR1(IIIc)
The MALDI-TOF data of the 55^60 kDa soluble FGFRs
were mapped to the unique sequence in the region encoded by
exon IIIc. Of the three potential tryptic peptides within this
region, we observed multiple fragments that matched two of
the three tryptic peptides (MH 1042.5, E[211^218]R+M[O];
MH 1915.5, T[202^218]R and MH 1931.8, T[202^
218]R+M[O]) (Fig. 3). An exact mass measurement obtained
on fragment MH 1042.5362 Da is within 0.7 ppm of the
calculated exact mass of the tryptic peptide (Table 2).
NanoESI tandem MS analyses also support the identi¢ca-
tion of soluble FGFR1(IIIc). The spectrum of the sequence-
speci¢c fragmentation pattern of the tryptic peptide, MH
1042.5362 Da, is shown in Fig. 5. The inset shows the frag-
ment ions that were found in the spectrum. The unlabeled
peaks consist of internal fragments.
Table 1
Amino acid sequences of the FGFR isoforms
FGFR1 Species Reference GenBank
accession
numbers
FGFR1(IIIa)-h5 Human [13] M34188
FGFR1(IIIc)-two Ig loop-h2 Human [13] M34185
FGFR1(IIIc)-three Ig loop-h1 Human [12] X52833
FGFR1(IIIb) Mousea [26] AAF05312
The amino acid sequences used for the mass mapping analyses were
derived from the GenBank accession numbers indicated in this ta-
ble.
aBecause the human sequence of exon IIIb is incomplete, we used
the murine sequence of exon IIIb. The murine sequence is 100% ho-
mologous to the human sequence in the corresponding regions.
Fig. 2. MALDI-TOF mass spectrum of the tryptic digests of the
55^60 kDa soluble FGFRs derived from calf serum. The monoiso-
topic mass was used to assign peaks with masses 6 1400.0 Da and
the average mass was used to assign peaks with masses s 1400.0
Da. 81% of the major peaks in the spectrum were identi¢ed. Due to
the heavily glycosylated nature of the soluble FGFRs, the unas-
signed peaks are attributed to incompletely deglycosylated fragment
ions or ions containing other post-translational modi¢cations.
Fig. 3. Peptide mass mapping of the tryptic digests of the 55^60 kDa soluble FGFRs to exons III(a^c) of FGFR1. The peptides con¢rmed by
peptide mass mapping are highlighted by capital letters. The small letters indicate fragment ions that were not observed. The putative carboxyl-
terminal cleavage site is indicated by an asterisk.
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3.3. Identi¢cation of a cleaved three Ig-like domain isoform of
FGFR1(IIIc)
The MALDI-TOF spectra of the 85 kDa protein sample
were mapped to the sequence in the extracellular domain of
the three Ig-like domain form of FGFR1(IIIc). 36% of the
extracellular domain of the three Ig-like domain form of
FGFR1 was matched. Two fragments were identi¢ed which
matched the unique peptide within the ¢rst Ig-like domain of
FGFR1, tryptic fragments (L[37^48]R) and an oxidized form
of the same fragment (L[37^48]R+16, W[O]). Another two
fragments were identi¢ed which span two of the three peptides
from the unique carboxyl-terminal amino acid sequence in
FGFR1(IIIc), tryptic peptides T[293^309]R and an oxidized
form of the same fragment, T[293^309]R+16, M[O] (Fig. 3).
These ionizable fragments were also detected in the MALDI-
TOF analysis of the 55^60 kDa soluble FGFR samples, sug-
gesting that calf serum contains both a two and a three Ig-like
domain isoform of FGFR(IIIc) which are proteolytically
cleaved from the transmembrane receptor.
3.4. Identi¢cation of a carboxyl-terminal peptide from a
cleaved two and three Ig-like domain isoform of
FGFR1(IIIb)
The MALDI-TOF data from both the 55 kDa and the 85
kDa soluble FGFR samples were mapped to the unique
sequence in the region coded by exon IIIb. One of three po-
tential tryptic peptides from this region was matched. This
peptide (MH 884.4568 = A[252^259]V) corresponds to a
carboxyl-terminal peptide containing a valine^methionine
cleavage site near the transmembrane domain of
FGFR1(IIIb) (Fig. 3). This fragment maps to the tryptic pep-
tide (ALEERPAV)1 which is just eight amino acids upstream
from the transmembrane domain of FGFR1. Although we
were unable to obtain MS/MS or PSD data on this peptide,
an exact mass measurement of this fragment (MH 884.4568)
was within 31 ppm of the calculated exact mass (Table 2).
This assignment is consistent with the report that a murine
transmembrane FGFR1^alkaline phosphatase fusion protein
can be cleaved in vitro by matrix metalloprotease-2 at an
identical site (valine^methionine), just eight amino acids
from the transmembrane domain [23].
4. Discussion
Since the initial identi¢cation of the soluble FGFRs in
blood, e¡orts to predict their biological activities have been
hampered by the incomplete chemical characterization of
these proteins within the second half of the third Ig-like do-
main, where alternative splicing leads to receptor variants
with di¡erent ligand binding properties. We have now
mapped the amino acid sequence of the soluble FGFRs in
this important region and show that the 55^60 kDa soluble
FGFRs consist of two Ig-like domain isoforms of
FGFR1(IIIa) and FGFR1(IIIc). The 85 kDa soluble FGFRs
consist of the three Ig-like domain isoform of FGFR1(IIIc).
The identi¢cation of a carboxyl-terminal peptide from
FGFR1(IIIb), which is cleaved from the transmembrane re-
ceptor at a valine^methionine bond [23], suggests that the two
and three Ig-like domain isoforms of soluble FGFR1(IIIb) are
also present in blood.
Our results indicate that soluble FGFRs are generated from
Table 2
Exact mass measurements of the soluble FGFRs
FGFR1 residues Observed mass Calculated mass Error (ppm) Isoform speci¢city
E[31^39]R 1074.5194 1074.5179 1.4 IIIa,b,c
E[213^220]R+M[O] 1042.5362 1042.5355 0.7 IIIc
E[85^91]R 928.4605 928.464 3.8 IIIa,b,c
E[216^228]R 1300.6826 1300.6861 2.7 IIIa
D[250^260]R 1217.6226 1217.6237 0.9 IIIa
D[49^60]R 1345.7039 1345.6823 16 domain I
A[252^259]V 884.4568 884.4841 31 IIIb
T[64^80]R 1832.9445 1832.9694 14 IIIa,b,c
I[191^203]K 1469.8819 1469.8369 31 IIIa,b,c
W[81^86]K 745.4107 745.4361 34 IIIa,b,c
The exact mass measurements were determined by MALDI-TOF using the re£ector mode with internal calibration as outlined in Section 2.
Fig. 4. MALDI-PSD mass spectrum of the tryptic peptide D[250^
260]R from the secreted FGFR(IIIa). The metastable ions resulting
from the breakdown of the tryptic peptide 1217.6. The inset shows
the expected sequence-speci¢c fragment ions that were found in the
spectrum. The fragmentation pattern corresponds to the a,b,c and
x,y,z series cleavage sites. If the charge on the fragment ion re-
mained on the N-terminus, the b series fragments (lower) are indi-
cated. If the charge of the fragment ion remained on the C-termi-
nus, the y series fragments (upper) are indicated. The peptide
sequence ions are assigned using the nomenclature proposed by Bie-
mann [22]. The additional peaks in the spectrum consist of ions
that were likely generated from other peptides that were within the
timed-ion selection window used to analyze the peptide of interest. 1 Trypsin does not cleave an arginine or lysine followed by a proline.
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the transmembrane FGFRs, FGFR1(IIIb) and FGFR1(IIIc),
by proteolytic cleavage at the cell surface. Proteolytic process-
ing of an extracellular domain at the cell surface is a common
mechanism for releasing many soluble receptors, membrane
bound growth factors and cell adhesion molecules and ap-
pears to be essential for normal physiologic growth, develop-
ment and the response to stress [5,6].
In addition to cleaved soluble receptors, our results show
that the secreted form of FGFR1(IIIa) circulates in blood.
This result was conclusive and surprisingly unexpected, pri-
marily because many soluble receptors that have been identi-
¢ed in vivo are produced by proteolytic cleavage at the cell
surface and not by the secretion of the products of alterna-
tively spliced mRNA transcripts [2,3]. However, tryptic frag-
ments from the unique region of FGFR1(IIIa) were found by
MS in three separate samples of puri¢ed material from calf
serum and the assignment was con¢rmed using PSD, which
gave an unequivocal fragmentation pattern of a tryptic pep-
tide (DLATSPRTSNR) within the secreted FGFR. Thus, we
conclude that both a secreted FGFR and multiple proteolyti-
cally cleaved FGFRs are present in calf serum. The secretion
of a product of an alternatively spliced transcript and the
proteolytic cleavage of full-length receptors are both mecha-
nisms used to generate the circulating FGFRs. The relative
contribution of each of these processes in vivo remains to be
determined.
While the biological relevance of the soluble FGFRs is still
unknown, it is intriguing to consider the possibility that the
soluble FGFRs regulate the biological activities of the FGFs
during growth and development. Using a semi-quantitative
immunoassay with fresh human plasma, we have detected
levels of the two and three Ig-like domain soluble FGFR
isoforms at more than 500 ng/ml each (unpublished data).
Such high circulating levels suggest that the soluble receptors
could play an important regulatory role, even if their a⁄nity
for the FGFs is less than the a⁄nities of the transmembrane
FGFRs, as reported for a variety of recombinant forms of the
soluble FGFRs [17,21,24]. Knowing the relative concentra-
tions of each of the ¢ve di¡erent soluble FGFR isoforms in
blood, their a⁄nities and ligand binding properties will give
additional insight into their biological relevance.
The potential importance of these proteins as regulators of
the FGF family members during growth and development is
further emphasized by the phenotype of transgenic mice that
overexpress a secreted form of FGFR2(IIIb) [25]. These non-
viable mice have multiple defects that occur during early or-
ganogenesis. Most of the developmental abnormalities are
consistent with an inhibition of FGFR signaling, indicating
that the soluble receptor transgene functions as a dominant
negative mutant and competes e¡ectively with the full-length
receptor for FGF binding. However, quite unexpectedly, the
phenotype also shows craniofacial and skeletal abnormalities,
which have also occurred with FGFR mutations that cause
constitutive activation of the transmembrane receptor. In the
future, it will be interesting to examine these e¡ects in more
detail and to determine how the soluble FGFRs regulate the
biological activity of the FGFs in a variety of developmental
and pathologic conditions.
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